What Is Foghorn Therapeutics Inc. (FHTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Foghorn Therapeutics Inc.'s intrinsic value is estimated at $1.68. Trading at its current price of $5.38, the valuation engine raises significant caution: 7 of 7 models flag downside risk, projecting an average implied return of -68.7%. Model dispersion is worth noting: PWERM targets $4.18 (-22.2%), versus ML-RIV at $0.75 (-86.0%). This +63.7% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About FHTX?
7 of 13 models are currently active for FHTX. All 7 active models suggest the stock trades above fair value. The Bayesian DCF estimates FHTX's intrinsic value at $0.93, implying -82.7% downside from the current price. See which stocks rank higher →
How Does FHTX Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, FHTX ranks #82 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Foghorn Therapeutics Inc., metrics like biosimilar competition timeline provide important context that general-purpose valuation models may underweight.
Is FHTX a Value Trap?
CirclFi's Value Trap algorithm assigns FHTX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Foghorn Therapeutics Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Foghorn Therapeutics Inc. scores 6.7 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +63.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every FHTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across FHTX's 7 active models, average confidence is 17%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad